Veea loses independent director, triggers Nasdaq governance cure period
Veea Inc. notified Nasdaq on June 2, 2026, that it fell out of compliance with three independent director requirements after board member Douglas Maine passed away on June 1, 2026. The company's six-member board now has only three independent directors, falling short of the majority-independent requirement and leaving the audit and compensation committees with insufficient independent members. Nasdaq provided a cure period extending to the earlier of the company's next annual shareholder meeting or May 31, 2027 (or November 27, 2026 if the annual meeting occurs before that date), and the company's stock remains listed on Nasdaq Capital Market pending compliance.
Key facts
- Douglas Maine, board member and member of audit committee and compensation committee, passed away on June 1, 2026
- Company notified Nasdaq on June 2, 2026, of noncompliance
- Board comprised of six directors, three of which are independent
- Audit committee has only two independent directors (requirement: at least three)
- Compensation committee has only one independent director (requirement: at least two)
- Cure period extends to the earlier of next Annual Meeting of Shareholders or May 31, 2027; or November 27, 2026 if annual meeting held before that date
- Nasdaq letter dated June 3, 2026
- Common stock trades on Nasdaq Capital Market under symbol VEEA; public warrants under symbol VEEAW
Why it matters
The company faces potential delisting if it cannot restore the required number of independent directors on its board and committees within the specified cure period, which could materially affect its listing status and trading access.
Developing story
- NT 10-K
- 8-Kthis filing
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-04. Not investment advice. View the source filing on SEC.gov →